Email Updates

You are here

MTN 015

Status
Ongoing
Phase
Other
Principal Investigator(s)
Sharon A. Riddler
Objective

A long-term observational study that seeks to understand the nature of HIV progression and treatment response among women who acquired HIV while taking part in an MTN parent study of ARV-based prevention products.

Results: MTN-015 was implemented initially at six African sites and enrolled 100/139 (72%) of eligible women who seroconverted in HIV Prevention Trials Network protocol 035 (HPTN 035, conducted by the MTN). The median time from seroconversion in HPTN 035 to enrollment in MTN-015 was 18 months.

 

 

Last updated May 10, 2021

August 2008
June 2019
Population
HIV positive
Sites

CAPRISA eThekwini Clinical Research Site

Durban, KwaZulu-Natal
South Africa

Makerere University - Johns Hopkins University Research Collaboration

Kampala
Uganda

South African Med Research Council - Botha's Hill

Durban
South Africa

South African Med Research Council - Isipingo

Durban
South Africa

South African Med Research Council - Tongaat

Durban
South Africa

South African Med Research Council - Umkomaas

Durban
South Africa

South African Med Research Council - Verulam

Durban
South Africa

South African Med Research Council- Overport

Durban
South Africa

University of North Carolina Project

Lilongwe
Malawi

UZ-UCSF HIV Prevention Trials Unit - Seke South

Chitungwiza
Zimbabwe

UZ-UCSF HIV Prevention Trials Unit - Spilhaus

Harare
Zimbabwe

Zengeza 3 Clinic

Harare
Zimbabwe

Wits Reproductive Health and HIV Institute / University of the Witwatersrand

Hillbrow
South Africa

Emavundleni Desmond Tutu HIV Centre CRS

Cape Town
South Africa

Chatsworth CRS

Chatsworth, KwaZulu-Natal
South Africa

Soweto MTN CRS

Johannesburg, Gauteng
South Africa